Sanofi and Earendil agree $2.56b bispecific antibodies deal
Earendil Labs and Sanofi have agreed a strategic collaboration to apply Earendil’s discovery platform to multiple autoimmune and inflammatory disease programmes. Sanofi will lead the development and worldwide commercialisation of bispecific candidates arising from the collaboration. According to the agreement Earendil Labs will receive up… Read More